Patents by Inventor Kirsten Dahl

Kirsten Dahl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Amylin and calcitonin receptor agonist
    Patent number: 10174082
    Abstract: The present invention relates to peptides comprising an amino acid sequence SEQ ID NO: 1 (EASELSTAALGRLSAELHELATLPRTETGPESP), analogs and derivatives thereof and pharmaceutical compositions comprising such peptides and derivatives. This invention further regards the use of these peptides according to SEQ ID NO: 1, analogs and derivatives thereof as medicaments.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: January 8, 2019
    Assignee: Novo Nordisk A/S
    Inventors: Thomas Kruse, Lauge Schaeffer, Kirsten Dahl, Christian Poulsen, Kirsten Raun
  • Novel Glucagon Analogues
    Publication number: 20170190757
    Abstract: The present invention relates to novel peptide compounds which have a protracted profile of action and improved solubility and stability, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity.
    Type: Application
    Filed: March 13, 2017
    Publication date: July 6, 2017
    Inventors: Jesper F. Lau, Thomas Kruse, Lars Linderoth, Henning Thoegersen, Jacob Kofoed, Kirsten Dahl
  • Novel Amylin And Calcitonin Receptor Agonist
    Publication number: 20170145059
    Abstract: The present invention relates to peptides comprising an amino acid sequence SEQ ID NO: 1 (EASELSTAALGRLSAELHELATLPRTETGPESP), analogues and derivatives thereof and pharmaceutical compositions comprising such peptides and derivatives. This invention further regards the use of these peptides according to SEQ ID NO: 1, analogues and derivatives thereof as medicaments.
    Type: Application
    Filed: January 27, 2017
    Publication date: May 25, 2017
    Inventors: Thomas Kruse, Lauge Schaeffer, Kirsten Dahl, Christian Poulsen, Kirsten Raun
  • Amylin and calcitonin receptor agonist
    Patent number: 9593149
    Abstract: The present invention relates to peptides comprising an amino acid sequence SEQ ID NO: 1 (EASELSTAALGRLSAELHELATLPRTETGPESP), analogs and derivatives thereof and pharmaceutical compositions comprising such peptides and derivatives. This invention further regards the use of these peptides according to SEQ ID NO: 1, analogs and derivatives thereof as medicaments.
    Type: Grant
    Filed: May 10, 2016
    Date of Patent: March 14, 2017
    Assignee: Novo Nordisk A/S
    Inventors: Thomas Kruse, Lauge Schaeffer, Kirsten Dahl, Kirsten Raun
  • Novel Glucagon Analogues
    Publication number: 20170051034
    Abstract: The present invention relates to novel peptide compounds which have a protracted profile of action and improved solubility and stability, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity.
    Type: Application
    Filed: September 12, 2016
    Publication date: February 23, 2017
    Inventors: Jesper F. Lau, Thomas Kruse, Lars Linderoth, Henning Thoegersen, Jacob Kofoed, Kirsten Dahl
  • Novel Amylin And Calcitonin Receptor Agonist
    Publication number: 20160272683
    Abstract: The present invention relates to peptides comprising an amino acid sequence SEQ ID NO: 1 (EASELSTAALGRLSAELHELATLPRTETGPESP), analogues and derivatives thereof and pharmaceutical compositions comprising such peptides and derivatives. This invention further regards the use of these peptides according to SEQ ID NO: 1, analogues and derivatives thereof as medicaments.
    Type: Application
    Filed: May 10, 2016
    Publication date: September 22, 2016
    Inventors: Thomas Kruse, Lauge Schaeffer, Kirsten Dahl, Christian Poulsen, Kirsten Raun
  • Novel Glucagon Analogues
    Publication number: 20160002311
    Abstract: The present invention relates to novel peptide compounds which have a protracted profile of action and improved solubility and stability, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity.
    Type: Application
    Filed: August 17, 2015
    Publication date: January 7, 2016
    Inventors: Jesper F. Lau, Thomas Kruse, Lars Linderoth, Henning Thoegersen, Jacob Kofoed, Kirsten Dahl
  • Amylin analogs and pharmaceutical compositions thereof
    Patent number: 9023789
    Abstract: The invention relates to polypeptides comprising an amino acid sequence which is an analog of human amylin, pharmaceutical compositions comprising these polypeptides, and these polypeptides for use as medicaments.
    Type: Grant
    Filed: September 24, 2013
    Date of Patent: May 5, 2015
    Assignee: Novo Nordisk A/S
    Inventors: Kirsten Dahl, Lauge Schaeffer, Thomas Kruse
  • Polypeptides
    Publication number: 20140087995
    Abstract: The invention relates to polypeptides comprising an amino acid sequence which is an analogue of human amylin, pharmaceutical compositions comprising these polypeptides, and these polypeptides for use as medicaments.
    Type: Application
    Filed: September 24, 2013
    Publication date: March 27, 2014
    Applicant: NOVO NORDISK A/S
    Inventors: Kirsten Dahl, Lauge Schaeffer, Thomas Kruse
  • Amylin analogues and pharmaceutical compositions thereof
    Patent number: 8575091
    Abstract: The invention relates to polypeptides comprising an amino acid sequence which is an analogue of human amylin, pharmaceutical compositions comprising these polypeptides, and these polypeptides for use as medicaments.
    Type: Grant
    Filed: June 28, 2013
    Date of Patent: November 5, 2013
    Assignee: Novo Nordisk A/S
    Inventors: Kirsten Dahl, Lauge Schaeffer, Thomas Kruse
  • POLYPEPTIDES
    Publication number: 20130281363
    Abstract: The invention relates to polypeptides comprising an amino acid sequence which is an analogue of human amylin, pharmaceutical compositions comprising these polypeptides, and these polypeptides for use as medicaments.
    Type: Application
    Filed: June 28, 2013
    Publication date: October 24, 2013
    Inventors: Kirsten Dahl, Lauge Schaeffer, Thomas Kruse
  • NOVEL GLUCAGON ANALOGUES
    Publication number: 20130035285
    Abstract: The present invention relates to novel peptide compounds which have a protracted profile of action and improved solubility and stability, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity.
    Type: Application
    Filed: March 28, 2011
    Publication date: February 7, 2013
    Applicant: Novo Nordisk A/S
    Inventors: Jesper F. Lau, Thomas Kruse, Lars Linderoth, Henning Thoegersen, Jacob Kofoed, Kirsten Dahl